异基因造血细胞移植后皮肤硬化治疗反应指标的对比研究
本研究利用慢性移植物抗宿主病联盟数据,在训练队列(183例)和验证队列(164例)中探索皮肤硬化特异性治疗反应指标。多因素模型保留患者关节活动度总分及其变化和NIH 0至3级皮肤变化(AUC训练0.83、验证0.75),患者报告指标模型保留人类活动概况调整活动评分、SF36活力变化、Lee症状量表皮肤评分及其变化(AUC训练0.86、验证0.75)。
要点
- 皮肤硬化是慢性GVHD的高致残亚型,现有NIH反应指标下治疗反应有限。
- 训练队列183例、验证队列164例,共纳入347例皮肤硬化患者。
- 验证队列中模型区分度有限,作者结论认为需进一步研究。
核心结论
- 识别了与6个月临床医生报告和患者报告治疗反应最相关的硬化指标,但基于验证队列表现认为需进一步研究。
- 可能需要新的反应指标来优化皮肤硬化的治疗反应评估。
研究设计与样本
- 利用慢性GVHD联盟数据,训练队列来自伊马替尼对比利妥昔单抗的随机试验及一项联盟观察性研究中的皮肤硬化患者,验证队列为另一项联盟观察性研究。
- 共纳入347例患者,训练队列183例,验证队列164例。
主要发现
- 单因素分析中多种皮肤和关节指标与临床医生报告反应相关,最终多因素模型保留患者关节活动度总分、患者关节活动度总分变化和NIH 0至3级皮肤变化,AUC训练队列0.83、验证队列0.75。
- 多种患者报告指标与患者报告反应相关,最终多因素模型保留人类活动概况调整活动评分、36项简短健康调查活力变化、Lee症状量表皮肤评分和Lee症状量表皮肤评分变化,AUC训练队列0.86、验证队列0.75。
局限性
- 基于验证队列中观察到的表现,作者结论认为需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cutaneous sclerosis, a highly morbid subtype of chronic graft-versus-host disease (GVHD), demonstrates limited treatment response under current National Institutes of Health (NIH) response measures. We explored novel sclerosis-specific response measures using Chronic GVHD Consortium data. A training cohort included patients with cutaneous sclerosis from a randomized trial of imatinib vs rituximab and a consortium observational study. The validation cohort was a different consortium observational study. Clinician-reported measures (baseline and baseline to 6-month change) were examined for association with 6-month clinician-reported response. Patient-reported measures (baseline and baseline to 6-month change) were studied for association with 6-month patient-reported response. A total of 347 patients were included (training 183 and validation 164). Although multiple skin and joint measures were associated with clinician-reported response on univariate analysis, patient range of motion (PROM) total score, PROM total score change, and NIH 0 to 3 skin change were retained in the final multivariate model (area under the receiver operating characteristic curve [AUC], 0.83 training and 0.75 validation). Similarly, many patient-reported measures were associated, but final multivariate analysis retained the human activity profile adjusted activity score (AAS), 36 item short form health survey (SF36) vitality change, Lee symptom scale (LSS) skin, and LSS skin change in the model (AUC, 0.86 training and 0.75 validation). We identified which sclerosis measures have the greatest association with 6-month clinician- and patient-reported treatment responses, a previously unstudied area. However, given the observed performance in the validation cohorts, we conclude that further work is needed. Novel response measures may be needed to optimally assess treatment response in cutaneous sclerosis.
引用
- Pidala JA, Onstad L, Baumrin E, et al. Comparison of treatment response measures in cutaneous sclerosis after allogeneic hematopoietic cell transplantation. Blood Adv. 2024. PMID: 38885484. doi:10.1182/bloodadvances.2024013233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。